HOUSTON, March 7, 2007 (PRIME NEWSWIRE) (PRIMEZONE) -- Encysive Pharmaceuticals Inc. (Nasdaq:ENCY) today announced that the Australian Therapeutic Goods Administration (TGA) has granted marketing approval for THELIN(r)(1) (sitaxentan sodium(2)) 100 mg tablets as a once daily oral treatment for patients with pulmonary arterial hypertension (PAH). THELIN is indicated for the treatment of PAH in patients with New York Heart Association (NYHA)/World Health Organization (WHO) functional class III symptoms to improve exercise ability. Efficacy has been shown in primary pulmonary hypertension(3) and in pulmonary hypertension associated with connective tissue disease. THELIN is the first selective endothelin A receptor antagonist and first once daily oral treatment available for patients with PAH.
